Cullinan Therapeutics Presents Preclinical Data for CLN-978
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will present new preclinical data for CLN-978, a novel investigational CD19xCD3 bispecific T cell engager, at the American College of Rheumatology (ACR) Convergence 2025.
- CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases.
- The data will be presented in a poster presentation session on October 28, 10:30 a.m.-12:30 p.m. CT (Poster Session C, Poster Number 2293).
- Cullinan will also have a Booth (#1074) in the Exhibit Hall.
No direct quotes available in the text.
Author's summary: Cullinan Therapeutics presents preclinical data for CLN-978 at ACR Convergence 2025.
More News
- Hugo Rodrigues: A nine-member Cornwall city council? That's disappointing
- Fraternity and hope strengthen relations between Catholics and Anglicans
- Why hasn’t Zohran Mamdani taken a position on the ballot proposals?
- Islamic Heritage Month event in Cornwall showcases how to build community
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- MCU: Jeremy Allen White Responds to Popular X-Men Fan Casting
- Eglin battalion chief and wife lose Crestview home to lightning strike, community rallies in support
- Time for Action: Investing in Health Canada to Accelerate Access to…
- Zorin OS Breaks Download Record as Windows 10 Users Seek Alternatives